Loading…
Jazz Pharmaceuticals plc is projected to rise to $306.01 by 2027, a +26% move from its current price of $243.82. JAZZ is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $240.71 | $244.02 | $247.37 | +0.08% |
| Jul 13 | $239.54 | $244.21 | $248.97 | +0.16% |
| Jul 14 | $238.70 | $244.41 | $250.26 | +0.24% |
| Jul 15 | $238.02 | $244.61 | $251.38 | +0.32% |
| Jul 16 | $237.44 | $244.80 | $252.39 | +0.40% |
| Jul 17 | $236.94 | $245.00 | $253.33 | +0.48% |
| Jul 18 | $236.50 | $245.20 | $254.22 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $236.50 | $245.20 | $254.22 | +0.56% |
| Week 2 | $234.30 | $246.58 | $259.50 | +1.13% |
| Week 3 | $232.93 | $247.97 | $263.98 | +1.70% |
| Week 4 | $231.99 | $249.37 | $268.06 | +2.28% |
| Week 5 | $231.32 | $250.78 | $271.88 | +2.85% |
| Week 6 | $230.84 | $252.19 | $275.53 | +3.43% |
| Week 7 | $230.50 | $253.62 | $279.05 | +4.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
In addition, the company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals plc is a healthcare company with a global portfolio of approved medicines and a pipeline under development. It trades under the symbol JAZZ and currently sits with a price of $240.97 per share and a market capitalization of $15.12B. The company_rank is 704.
The forecast implies a bullish longer-term price trajectory, with notable milestones such as 2027 avg of $307.20, 2028 avg of $392.76, 2029 avg of $505.58, 2030 avg of $583.55, 2040 avg of $1,878.73, and 2050 avg of $4,512.35, with corresponding ROIs and bullish sentiment across the horizon. Sentiment is forecast to be BULLISH for 2027 onward, reflecting meaningful upside potential over time.
A major floor 26.8% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
Price is pressing into resistance (1.8% away) — a breakout level to watch.
A major ceiling 7.7% above — clearing it would confirm fresh momentum.
Key JAZZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JAZZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $246.17 | Sell | $244.84 | Sell |
| MA 10 | $242.06 | Buy | $242.07 | Buy |
| MA 20 | $235.43 | Buy | $238.06 | Buy |
| MA 50 | $231.01 | Buy | $228.36 | Buy |
| MA 100 | $209.50 | Buy | $212.61 | Buy |
| MA 200 | $182.71 | Buy | $189.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.08 | Neutral |
| Stoch RSI (14) | 64.99 | Neutral |
| CCI (20) | 77.24 | Neutral |
| Williams %R (14) | -19.84 | Info |
| MACD (12,26,9) | 1.08 | Buy |
| ROC (12) | 5.89 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 80.16 | Sell |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | 11.06 | Buy |
| Ultimate (7,14,28) | 61.27 | Neutral |
| Momentum (10) | 17.62 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 248.63 | Sell |
| ADX (14) | 20.56 | Buy |
| ATR (14) | 3.03 | Info |
The near-term technical picture is bullish. The RSI(14) is 60, indicating moderate bullish momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $160.25 | $243.82 | $335.69 | 0% | Neutral | |
| $250.61 | $306.01 | $390.66 | +26% | Bullish | |
| $310.81 | $386.65 | $506.95 | +59% | Bullish | |
| $396.86 | $501.29 | $671.26 | +106% | Bullish | |
| $449.72 | $575.74 | $784.83 | +136% | Bullish | |
| $533.77 | $691.68 | $957.78 | +184% | Bullish | |
| $594.50 | $779.08 | $1,094.15 | +220% | Bullish | |
| $619.90 | $820.94 | $1,167.85 | +237% | Bullish | |
| $697.13 | $932.39 | $1,342.25 | +282% | Bullish | |
| $781.06 | $1,054.52 | $1,534.97 | +333% | Bullish | |
| $1,273.85 | $1,793.80 | $2,736.25 | +636% | Bullish | |
| $2,873.69 | $4,339.98 | $7,096.32 | +16.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $160.25 | $243.82 | $296.25 | +0.00% |
| August 2026 | $223.08 | $261.16 | $312.39 | +7.11% |
| September 2026 | $223.05 | $262.37 | $316.27 | +0.46% |
| October 2026 | $221.88 | $262.07 | $317.98 | -0.11% |
| November 2026 | $227.16 | $269.23 | $328.47 | +2.73% |
| December 2026 | $230.24 | $273.76 | $335.69 | +1.68% |
Click any year to see its month-by-month JAZZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The JAZZ price prediction for 2026 points to an average of $243.82 (low $160.25, high $335.69) — a potential gain of 0% on today's $243.82. Price action looks broadly range-bound.
In 2027, JAZZ is projected to trade between $250.61 and $390.66, averaging $306.01 — a potential gain of +26% from today's $243.82. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Jazz Pharmaceuticals plc's 2028 outlook centres on $386.65, within a $310.81 to $506.95 range. That is up +26% on the projected 2027 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2029, JAZZ could reach as high as $671.26, with a base case around $501.29 and support toward $396.86 — roughly +106% from $243.82. Buyers look set to stay in control over this stretch.
Expect JAZZ to range from $449.72 to $784.83 through 2030. The $575.74 average target implies a +136% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The JAZZ price prediction for 2031 points to an average of $691.68 (low $533.77, high $957.78) — a potential gain of +184% on today's $243.82. Buyers look set to stay in control over this stretch.
In 2032, JAZZ is projected to trade between $594.50 and $1,094.15, averaging $779.08 — a potential gain of +220% from today's $243.82. That is up +13% on the projected 2031 average. Momentum favours further upside here.
Jazz Pharmaceuticals plc's 2033 outlook centres on $820.94, within a $619.90 to $1,167.85 range. That is up +5% on the projected 2032 average. That marks a +237% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, JAZZ could reach as high as $1,342.25, with a base case around $932.39 and support toward $697.13 — roughly +282% from $243.82. Momentum favours further upside here.
Expect JAZZ to range from $781.06 to $1,534.97 through 2035. The $1,054.52 average target implies a +333% move from current prices. That is up +13% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The JAZZ price prediction for 2040 points to an average of $1,793.80 (low $1,273.85, high $2,736.25) — a potential gain of +636% on today's $243.82. Momentum favours further upside here.
In 2050, JAZZ is projected to trade between $2,873.69 and $7,096.32, averaging $4,339.98 — a potential gain of +16.8x from today's $243.82. That is up +142% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JAZZ today (≈ 4.101386 JAZZ) could be worth
$17,799.95
+$16,799.95 (+1680%) by 2050 · US Dollar
Based on the average projected JAZZ price of $4,339.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JAZZwould be worth at today's price.
$1,000 invested in JAZZ on Jul 10, 2025 (≈ 8.890469 JAZZ) would be worth
$2,167.67
+$1,167.67 (+116.8%) today · 2.17× · US Dollar
Based on a JAZZ entry price of $112.48 vs. today's $243.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $243.47 | $1,001.44 | +0.1% |
| 1 month ago | $229.63 | $1,061.8 | +6.2% |
| 3 months ago | $194.2 | $1,255.51 | +25.6% |
| 6 months ago | $163.68 | $1,489.61 | +49.0% |
| 1 year ago | $112.48 | $2,167.67 | +116.8% |
| All time (5.0y) ago | $184.79 | $1,319.44 | +31.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JAZZ forecast.
Our base-case forecast reaches $490.00 around 2029.
Implied market cap at $490.00: $30.74B
The multi-year forecast shows a clear bullish trajectory with rising averages: 2027 avg $307.20; 2028 avg $392.76; 2029 avg $505.58; 2030 avg $583.55; 2031 avg $709.28; 2032 avg $792.44; 2033 avg $835.87; 2034 avg $963.67; 2035 avg $1,086.98; 2040 avg $1,878.73; 2050 avg $4,512.35. The corresponding ROIs are 27.5%, 63%, 109.8%, 142.2%, 194.3%, 228.8%, 246.9%, 299.9%, 351.1%, 679.6%, and 1772.6% respectively, with a bullish sentiment indicated for 2027 through 2050. These projections illustrate a significant long-term upside, but they are estimates and not guarantees; actual results depend on market conditions and the company’s execution.
Tap a question to reveal the answer.
The 2030 forecast lists min $455.66, avg $583.55, max $795.84, with ROI 142.2% and sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs (e.g., 2027 avg $307.20, ROI 27.5%; 2028 avg $392.76, ROI 63%; 2029 avg $505.58, ROI 109.8%; 2030 avg $583.55, ROI 142.2%; 2040 avg $1,878.73, ROI 679.6%; 2050 avg $4,512.35, ROI 1772.6%).
Yes, the forecast shows a max price of $1,582.68 in 2035 and $2,866.46 in 2040, and $7,379.35 in 2050, with 2035 avg $1,086.98.
Current price is $240.97.
RSI(14) is 60; SMA(50) is $224.89; SMA(200) is $178.64; 30-day range low $218.21 and high $266.11; support $224.66; resistance $240.97; sentiment BULLISH.
Jazz Pharmaceuticals plc Community Discussion
0Share your Jazz Pharmaceuticals plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.